Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6870810 Mono/Combo in Advanced Multiple Myeloma
NCT03068351Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of RO-6870810 in multiple myeloma (MM) (2 arms), sponsored by Roche. Primary endpoints: Number of Dose-Limiting Toxicities at 1 year, Objective Response Rate at 2.5 years and 3 more. Started Jun 2017; status: completed.
02
Drugs
RO-6870810
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03068351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068351.